Study
12‑weeks fisetin supplementation and interval resistance with aerobic training: changes in Maresin‑1 and inflammatory markers in men with obesity: a randomized controlled trial.
In 44 obese men, 200 mg/day fisetin plus 12 weeks of training produced the largest reductions in glucose, insulin and HOMA-IR.
Summary Can fisetin and exercise improve blood sugar and inflammation in obese men? Show / hide ↓
Researchers randomly assigned 44 adult men with obesity to take fisetin, exercise, both, or a placebo, an inactive treatment, for 12 weeks. Fisetin was taken at 200 milligrams daily. The exercise program combined weight training with interval aerobic exercise, meaning repeated periods of harder and easier activity. The researchers measured blood sugar, insulin, HOMA-IR, a score showing how resistant the body is to insulin, and inflammation-related substances including Maresin-1, IL-6, and TNF-alpha. All active treatments improved several measures, and the combination of fisetin and exercise produced the largest reported drops in blood sugar, insulin, and HOMA-IR, while exercise increased Maresin-1.
What this means for you: This small, short study does not show that fisetin is worth buying, especially because it did not report the actual size of most improvements or direct comparisons between groups. Regular exercise has broader evidence behind it, but fisetin’s benefits remain uncertain.
early evidenceForty-four obese adult men completed a 12-week, four-arm randomised trial of placebo, fisetin alone, concurrent interval resistance-aerobic training with placebo, or the same training with fisetin. Fisetin was given at 200 mg/day. Training combined eight resistance exercises at 60% of one-repetition maximum with progressive aerobic work at 50% to 70% of maximum heart rate. The study measured Maresin-1, IL-6, TNF-α, fasting blood glucose, insulin, and HOMA-IR before and after treatment. Group-by-time interactions were reported for every listed marker: Maresin-1 p=0.034, and IL-6, TNF-α, glucose, insulin, and HOMA-IR each p=0.001. Maresin-1 rose in both training groups. IL-6 fell with training, training plus fisetin, and fisetin alone; TNF-α fell in all active groups. Glucose, insulin, and HOMA-IR declined in all active arms, with the largest reductions in the combined training-fisetin group. The abstract does not give the size of those reductions or direct pairwise comparisons. This is a short metabolic-biomarker study in obese men, not evidence of disease prevention or longer life.
Twelve weeks of concurrent interval resistance-aerobic training, especially when combined with fisetin, improved inflammatory and metabolic markers in obese men.
N was 44, all participants were obese adult men, and the follow-up was only 12 weeks. The endpoints were circulating markers and insulin-resistance estimates rather than clinical outcomes, and the design cannot cleanly separate fisetin from training effects.
Cited by
1 encyclopedia entries reference this study.